





A unit of Artemis Medicare Services Ltd.

May 12, 2025

The Secretary, National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 The Secretary, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

**NSE Code: ARTEMISMED** 

**Scrip Code: 542919** 

Sub: Press Release

Dear Sir/Ma'am,

With reference to the captioned subject, please find attached herewith a press release regarding financial results for quarter/year ended March 31, 2025, being issued by the Company.

Submitted for your information & records.

Thanking you.

Yours Faithfully, For Artemis Medicare Services Limited

Poonam Makkar Company Secretary & Compliance Officer

**Encl.: As above** 













# Artemis' consolidated gross revenue up 7% in Q4; EBITDA up 21%; Net Profit up 60%

May 12, 2025: The Board of Directors of Artemis Medicare Services Ltd today approved the company's audited financial results for the  $4^{th}$  quarter (Jan to Mar) and 12M (Apr to Mar) for the financial year 2024 – 25.

For the quarter ended March 31, 2025 Artemis Medicare Services Ltd, on a consolidated level, registered a gross revenue of Rs 2,521 Million, an increase of 7.0% over the same period last fiscal. For the fiscal year (April – March), the company's gross revenue closed at Rs 9,819 Million, an increase of 6.5% over the same period last fiscal. The Board of Directors have recommended a final dividend of 45% per Equity Share of face value of Re 1 each for FY25, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the Company.

## **Quarterly Artemis Hospital Gurgaon Performance Highlights**

Q4 FY2024-25 (Jan-Mar) vs Q4 FY2023-24

- Average gross revenue per occupied bed (ARPOB) was at Rs 82,800, as against Rs 78,800
- Net Revenue from operations was up 8.0% to close at Rs 2,252 Million, as against Rs 2,086 Million in Q4 FY24
- EBITDA reported was Rs 481 Million at a margin of 21.4%, as against Rs 400 Million
- Bed capacity utilisation, including that for the new towers stood at 60.8%
- Revenues from overseas patients increased by 26.5% to Rs 725 Million from Rs 573 Million
- Overseas patients contributed 32% to Net Revenue
- Patient footfall of 93,443 and 3,340 surgeries performed
- Average length of stay (ALOS) at 3.6 days compared to 3.8 days

## **Quarterly Consolidated Performance Highlights**

Q4 FY2024-25 (Jan-Mar) vs Q4 FY2023-24

- Net Revenue from operations was up 6.5% to close at Rs 2,399 Million, as against Rs 2,252
   Million in Q4 FY24
- EBITDA reported was Rs 482 Million at a margin of 20.1%, as against Rs 399 Million
- Net profit for Q4 closed at Rs 229 Million, as against Rs 143 Million in the Q4 FY24

## 12 Months Consolidated Performance Highlights

FY 2024-25 (April-Mar) vs FY 2023-24

- Net Revenue from operations was up 6.6% to close at Rs 9,369 Million, as against Rs 8,786
   Million in FY24
- EBITDA reported was Rs 1,848 Million at a margin of 19.7%, as against Rs 1,401 Million
- Net profit for 12 Months closed at Rs 822 Million, as against Rs 491 Million in the same period last fiscal

Commenting on the company's performance, **Onkar Kanwar**, **Chairman**, **Artemis Medicare Services Ltd** said "Artemis concluded FY25 on a strong and positive trajectory, delivering consistent performance and steady growth across the year. We have continued to advance in both clinical excellence and operational capabilities, reaffirming our commitment to provide high-quality, accessible healthcare to the communities we serve. During the year we also inaugurated our third tower, which will be commissioned in a phase-wise manner to accommodate the increasing demand from our growing patient base.

To fuel our next growth phase, we raised Rs 330 Crores from the International Finance Corporation (IFC), enabling strategic expansion across Delhi NCR and select Tier 2 cities through both brownfield and greenfield projects. The Board has approved a long-term



# **Media Release**

Operations & Management and Medical Services Agreement for a 300+ bed super-speciality hospital in Raipur. This deal marks a key step in expanding our footprint in Central India and reinforces our mission to deliver advanced healthcare solutions across geographies.

As we look ahead, our unwavering focus remains on creating long-term value for our patients, shareholders, and employees, while building Artemis into one of India's most trusted and respected healthcare brands."

# Key consolidated financials:

	Rs	Rs Million		Rs Crores	
FY 2024-25	Q4	12M	Q4	12M	
Gross Revenue	2,521	9,819	252.1	981.9	
EBITDA	482	1,848	48.2	184.8	
Net Profit	229	822	22.9	82.2	

#### For further information, please contact:

Sanjiv K Kothari,

Chief Financial Officer Artemis Medicare Services Ltd.

+91 124 4511 111

Sanjiv.kothari@artemishospitals.com

Simran Malhotra / Anvita Raghuram

Churchgate Partners

+91 22 6169 5988

<u>Artemisteam@churchgatepartners.com</u>

### About Artemis Medicare Services Ltd

Artemis Medicare Services Ltd operates 800+ beds predominantly in the Delhi NCR region, including a 700+ bed quaternary care, super speciality hospital accredited by JCI and NABH. Additionally, the Company runs a JV with Philips under the Artemis Cardiac Care brand. Artemis also has overseas presence in Mauritius through an operations and management arrangement.

Artemis Medicare Services Ltd., Sector 51, Gurugram 122001, India, T: +91 124 4511 111
www.artemishospitals.com | www.facebook.com/ArtemisHospitals | www.linkedin.com/company/artemishospital